Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 176

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 176
---
 $
        116,277

        $
        66,934

        $
        —

        As of December 31, 2023(in thousands)

        CarryingAmount

        Gross Unrealized Gains

        Gross Unrealized Losses

        FairValue

        QuotedPriced inActiveMarkets(Level 1)

        SignificantOtherObservableInputs(Level 2)

        SignificantUnobservableInputs(Level 3)

        Financial assets

        Money market funds
         
        $
        37,694

        $
        —

        $
        —

        $
        37,694

        $
        37,694

        $
        —

        $
        —

        Corporate securities

        69,995

        48

        —

        70,043

        5,577

        64,466

        —

        Government securities

        120,670

        143

        —

        120,813

        92,297

        28,516

        —

        Total financial assets
         
        $
        228,359

        $
        191

        $
        —

        $
        228,550

        $
        135,568

        $
        92,982

        $
        —

 113

Cash and Cash Equivalents – As of December 31, 2024, the Company had aggregate cash and cash equivalents of $40,876, including cash equivalents of $40,790, consisting of money market funds. As of December 31, 2023, the Company had aggregate cash and cash equivalents of $37,706, including cash equivalents of $37,694, consisting of money market funds.Marketable Securities – Marketable securities of $142,421 as of December 31, 2024, consisted of corporate debt securities of $32,949 and government debt securities of $109,472. There were $128,578 current marketable securities and $13,843 noncurrent marketable securities as of December 31, 2024. Marketable securities of $190,856 as of December 31, 2023, consisted of corporate debt securities of $70,043 and government debt securities of $120,813. There were $165,351 current marketable securities and $25,505 noncurrent marketable securities as of December 31, 2023.As of December 31, 2024 and 2023, aggregated gross unrealized losses of available-for-sale investments were